AbbVie Reports Third-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Abbvie (ABBV) PT Lowered to $71 at BMO Capital
November 5, 2018 8:47 AM ESTBMO Capital analyst Alex Arfaei lowered the price target on Abbvie (NYSE: ABBV) to $71.00 (from $78.00) while maintaining a Underperform rating.
The analyst commented, "3Q18 was fine, but not great; particularly the Imbruvica beat. The market is ignoring management's long-term guidance, and signals of... More
AbbVie (ABBV) Tops Q3 EPS by 12c, Lifts FY EPS Guidance
November 2, 2018 7:48 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $2.14, $0.12 better than the analyst estimate of $2.02. Revenue for the quarter came in at $8.24 billion versus the consensus estimate of $8.22 billion.
GUIDANCE:
AbbVie sees Q4 2018 EPS of $7.90-$7.92, versus the consensus of $7.88.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More